Serum markers of bone turnover in dialyzed patients separated according to age

International Urology and Nephrology

Volumn 38, Issue 2, 2006, Pages 311-316

  Grzegorzewska, Alicja E ^a   Młot, Monika ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Age; Cyclase activating parathyroid hormone; Dialysis; Intact parathyroid hormone; Osteoprotegrin; Osteoprotegrin ligand

Indexed keywords

BIOLOGICAL MARKER; PARATHYROID HORMONE; PROTEGRIN;

ADULT; AGED; AGING; ARTICLE; BLOOD SAMPLING; BONE CELL; BONE TURNOVER; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GENDER; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; PARACRINE SIGNALING; PARATHYROID HORMONE BLOOD LEVEL; PERITONEAL DIALYSIS; PROTEIN BLOOD LEVEL; RISK FACTOR; TREATMENT DURATION;

ADULT; AGE FACTORS; AGED; AGING; BIOLOGICAL MARKERS; BONE REMODELING; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PARATHYROID HORMONE; PERITONEAL DIALYSIS; RENAL DIALYSIS;

EID: 33746531137     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11255-006-0079-1     Document Type: Article

References (35)

1. ES Oh EJ Rhee KW Oh WY Lee KH Baek KH Yoon et al. 2005 Circulating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women Metabolism 54 49-54 15562379 1:CAS:528:DC%2BD2cXhtVansbrN 10.1016/j.metabol.2004.08.005
2. A Fahrleitner-Pammer H Dobnig C Piswanger-Soelkner C Bonelli HP Dimai G Leb et al. 2003 Osteoprotegerin serum levels in women: Correlation with age, bone mass, bone turnover and fracture status Wien Klin Wochenschr 115 291-297 12793029 1:CAS:528:DC%2BD2cXltVen
3. L Pulsatelli P Dolzani T Silvestri P Caraceni A Facchini G Ravaglia et al.2004 Soluble receptor activator of nuclear factor- kappaB ligand (sRANKL)/osteoprotegerin balance in ageing and age-associated diseases Biogerontology 5 119-127 15105586 1:CAS:528:DC%2BD2cXjtlCgs70%3D 10.1023/ B:BGEN.0000025075.04136.ec
4. JM Liu HY Zhao G Ning YJ Zhao Y Chen LZ Zhang et al. 2004 The relationships between changes of serum osteoprotegerin, nuclear factor-kappa B ligand receptor activator, and age, menopause, bone biochemical markers and bone mineral densities in women aged 20-75 Zhonghua Nei Ke Za Zhi 43 447-450 15312444 1:CAS:528:DC%2BD2cXot1Kqsr4%3D
5. T Ueland K Brixen L Mosekilde L Mosekilde A Flyvbjerg J Bollerslev 2003 Age-related changes in cortical bone content of insulin-like growth factor binding protein (IGFBP)-3, IGFBP-5, osteoprotegerin, and calcium in postmenopausal osteoporosis: A cross-sectional study J Clin Endocrinol Metab 88 1014-1018 12629078 1:CAS:528:DC%2BD3sXit1egtbk%3D 10.1210/jc.2002-020977
6. S Kudlacek B Schneider W Woloszczuk P Pietschmann R Willvonseder 2003 Serum levels of osteoprotegerin increase with age in a healthy adult population Bone 32 681-686 12810175 1:CAS:528:DC%2BD3sXks1WksLc%3D 10.1016/S8756-3282(03)00090-5
7. M Haas Z Leko-Mohr P Roschger J Kletzmayr C Schwarz C Domenig et al. 2002 Osteoprotegrin and parathyroid hormone as markers of high-bone turnover osteodystrophy and decreased bone mineralization in hemodialysis patients Am J Kidney Dis 39 580-586 11877577 1:CAS:528:DC%2BD38Xit1eitb0%3D 10.1053/ajkd.2002.33386
8. G Coen P Ballanti A Balducci S Calabria MS Fischer L Jankovic et al. 2002 Serum osteoprotegrin and renal osteodystrophy Nephrol Dial Transplant 17 233-238 11812872 1:CAS:528:DC%2BD38XitVSnsrw%3D 10.1093/ ndt/17.2.233
9. KB Tan J Harrop M Reddy P Young J Terrett J Emery et al. 1997 Characterization of novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells Gene 204 35-46 9434163 1:CAS:528:DyaK1cXivFWhsg%3D%3D 10.1016/ S0378-1119(97)00509-X
10. H Yasuda N Shima N Nakagawa SI Mochizuki K Yano N Fujise et al. 1998 Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegrin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro Endocrinology 39 1329-1337 10.1210/ en.139.3.1329
11. BS Kown S Wang N Udagawa V Haridas ZH Lee KK Kim et al. 1998 TR1, a new member of the tumor necrosis factor receptor family, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption FASEB J 12 845-854
12. LC Hofbauer CR Dunstan TC Spelsberg BL Riggs S Khosla 1998 Osteoprotegrin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines Biochem Biophys Res Commun 250 776-781 9784422 1:CAS:528:DyaK1cXmsF2qtr4%3D 10.1006/bbrc.1998.9394
13. LC Hofbauer S Kholsa CR Dunstan DL Lacey TC Spelsberg BL Riggs 1999 Estrogen stimulates gene expression and protein production of osteoprotegrin in human osteoblastic cells Endocrinology 140 4367-4370 10465311 1:CAS:528:DyaK1MXlslSqsLw%3D 10.1210/en.140.9.4367
14. T Murakami M Yamamoto M Yamamoto K Ono M Nishikawa N Nagata et al. 1998 Transforming growth factor-β1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteocleast-like cells Biochem Biophys Res Commun 252 747-752 9837778 1:CAS:528:DyaK1cXnvF2gt7Y%3D 10.1006/ bbrc.1998.9723
15. NOA Vidal H Brändström KB Jonsson C Ohlsson 1998 Osteoprotegrin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids J Endocrinol 159 191-195 9795357 1:CAS:528:DyaK1cXmsFOnurs%3D 10.1677/joe.0.1590191
16. 2 in human bone marrow stroma cells Biochem Biophys Res Commun 247 338-341 9642127 10.1006/bbrc.1998.8783
17. HL Tan G Van S Scully G Shimamoto M Kelley B Boyle et al. 1997 Recombinant osteoprotegrin (OPG), a novel TNF-receptor family member, inhibits in vitro murine osteoclast formation from bone marrow precursors (abstract P213) J Bone Miner Res 12 1 Suppl S155
18. Y Hakeda Y Kobayashi K Yamaguchi H Yasuda E Tsuda K Higashio et al. 1998 Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts Biochem Biophys Res Commun 251 796-801 9790989 1:CAS:528:DyaK1cXntlaisbc%3D 10.1006/ bbrc.1998.9523
19. T Akatsu T Murakami M Nishikawa K Ono N Shinomiya E Tsuda et a. 1998 Osteoclastogenesis-inhibitory factor supresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast Biochem Biophys Res Commun 250 229-234 9753612 1:CAS:528:DyaK1cXmt1ygs7Y%3D 10.1006/bbrc.1998.9294
20. K Fuller B Wong S Fox Y Choi TJ Chambers 1998 TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts J Exp Med 188 997-1001 9730902 1:CAS:528:DyaK1cXmtVagtb8%3D 10.1084/jem.188.5.997
21. MC Faugere M Langub HH Malluche 2001 The effects of PTH-(1-84) on bone turnover are antagonized by PTH-(7-84) in thyroparathyroidectomized and nephrectomized rats Abstr J Am Soc Nephrol 12 764A
22. L Nguyen-Yamamoto L Rousseau JH Brossard R Lepage P D'Amur 2001 Synthetic carboxyl-terminal fragments of parathyroid hormone (PTH) decrease ionised calcium concentration in rats by acting on receptor different from the PTH/PTH-related peptide receptor Endocrinology 142 1386-1392 11250917 1:CAS:528:DC%2BD3MXitlemtLg%3D 10.1210/en.142.4.1386
23. P Divieti MR John H Juppner FR Bringhurst 2002 Human PTH-(7-84) inhibits bone resorption in vitro via actions independent of the type 1 PTH/PTHrP receptor Endocrinology 143 171-176 11751606 1:CAS:528:DC%2BD38XjtVOqsA%3D%3D 10.1210/en.143.1.171
24. Cantor T. The clinical application of cyclase activating PTH assay and the inhibitor ratio. 23rd Annual Conference on Peritoneal Dialysis 2003 Mar 2-4; Seattle. Columbia: School of Medicine--University of Missouri, 2003
25. Amerling R. What is the 3rd generation PTH assay and how do 3rd generation assays differ? 24th Annual Conference on Peritoneal Dialysis 2004 Feb 9-11; San Antonio. Columbia: School of Medicine--University of Missouri, 2004
26. MC Monier-Faugere Z Geng H Mawad RM Friedler P Gao TL Cantor et al. 2001 Improved assessment of bone turnover by the PTH- (1-84)/large C-PTH fragments ratio in ESRD patients Kidney Int 60 1460-1468 11576360 1:CAS:528:DC%2BD3MXnsFSju7o%3D 10.1046/j.1523-1755.2001.00949.x
27. MC Faugere Z Geng H Mawad RM Friedler P Gao T Cantor et al. 2001 Improved assessment of bone turnover by the PTH 1-84/large C-PTH fragments ratio in ESRD patients Kidney Int 60 460-468
28. Cantor T. What to look assessing the value of existing or new PTH test. 24th Annual Conference on Peritoneal Dialysis 2004 Feb 9-11; San Antonio. Columbia: School of Medicine--University of Missouri, 2004
29. P Gao S Scheibel P D'Amur MR John SD Rao H Schmidt-Gayk et al. 2001 Development of the novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: Implications for improvement of accurate assessment of parathyroid function J Bone Miner Res 16 605-614 11315988 1:CAS:528:DC%2BD3MXislCksbg%3D 10.1359/ jbmr.2001.16.4.605
30. AE Grzegorzewska M Młot 2004 Ratio of cyclase activating and cyclase inactive parathormone (CAP/CIP) in dialysis patients: correlations with other markers of bone disease Ann Acad Med Bialostocensis 49 190-192 1:CAS:528:DC%2BD2MXks1GisQ%3D%3D
31. Spiechowicz U, Kokot F, Wiecek A. Function of parathyroid glands in kidney transplant patients--diagnostic value of CAP and CIP. Abstr The 2nd Poland-Korea Seminar on Renal Replacement Therapy Seoul 2004;p21
32. S Trofimov IA Pantsulaia E Kobyliansky G Livshits 2004 Circulating levels of receptor activator of nuclear factor-kappaB ligand/ osteoprotegerin/macrophage-colony stimulating factor in a presumably healthy human population Eur J Endocrinol 150 305-311 15012615 1:CAS:528:DC%2BD2cXivFCktrk%3D 10.1530/eje.0.1500305
33. D Grigorie E Neacsu M Marinescu O Popa 2003 Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis Rom J Intern Med 41 409-415 15526523 1:CAS:528:DC%2BD2cXntVels70%3D
34. KW Oh EJ Rhee WY Lee SW Kim ES Oh KH Baek et al. 2004 The relationship between circulating osteoprotegerin levels and bone mineral metabolism in healthy women Clin Endocrinol (Oxf) 61 244-249 1:CAS:528:DC%2BD2cXnslWlt7o%3D 10.1111/j.1365-2265.2004.02090.x
35. G Schett S Kiechl K Redlich F Oberhollenzer S Weger G Egger et al. 2004 Soluble RANKL and risk of nontraumatic fracture JAMA 291 1108-1113 14996780 1:CAS:528:DC%2BD2cXhvFenurc%3D 10.1001/jama.291.9.1108